CADTH Reimbursement Review - Dupilumab (Dupixent) - Sponsor: Sanofi-Aventis Canada Inc. Therapeutic area: Asthma

If your institution is a member, please log into Canada Commons from a link provided by your institution. This typically involves logging in via a menu managed by your library.

Accessing this content requires a membership

If your institution is a member, please log into Canada Commons from a link provided by your institution. This typically involves logging in via a menu managed by your library.